BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 21116279)

  • 1. Hypermethylation of specific microRNA genes in MLL-rearranged infant acute lymphoblastic leukemia: major matters at a micro scale.
    Stumpel DJ; Schotte D; Lange-Turenhout EA; Schneider P; Seslija L; de Menezes RX; Marquez VE; Pieters R; den Boer ML; Stam RW
    Leukemia; 2011 Mar; 25(3):429-39. PubMed ID: 21116279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options.
    Stumpel DJ; Schneider P; van Roon EH; Boer JM; de Lorenzo P; Valsecchi MG; de Menezes RX; Pieters R; Stam RW
    Blood; 2009 Dec; 114(27):5490-8. PubMed ID: 19855078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia.
    Schotte D; Lange-Turenhout EA; Stumpel DJ; Stam RW; Buijs-Gladdines JG; Meijerink JP; Pieters R; Den Boer ML
    Haematologica; 2010 Oct; 95(10):1675-82. PubMed ID: 20494936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting.
    Schafer E; Irizarry R; Negi S; McIntyre E; Small D; Figueroa ME; Melnick A; Brown P
    Blood; 2010 Jun; 115(23):4798-809. PubMed ID: 20215641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants.
    Driessen EM; van Roon EH; Spijkers-Hagelstein JA; Schneider P; de Lorenzo P; Valsecchi MG; Pieters R; Stam RW
    Haematologica; 2013 Jun; 98(6):937-44. PubMed ID: 23403319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of the let-7b microRNA pathway by DNA hypermethylation in infant acute lymphoblastic leukemia with MLL gene rearrangements.
    Nishi M; Eguchi-Ishimae M; Wu Z; Gao W; Iwabuki H; Kawakami S; Tauchi H; Inukai T; Sugita K; Hamasaki Y; Ishii E; Eguchi M
    Leukemia; 2013 Feb; 27(2):389-97. PubMed ID: 22918121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia.
    Stumpel DJ; Schneider P; Pieters R; Stam RW
    Eur J Cancer; 2015 Sep; 51(14):2008-21. PubMed ID: 26188848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia.
    Stam RW; den Boer ML; Passier MM; Janka-Schaub GE; Sallan SE; Armstrong SA; Pieters R
    Leukemia; 2006 Feb; 20(2):264-71. PubMed ID: 16357833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of global hypomethylation in promoter hypermethylated Mixed Lineage Leukaemia-rearranged infant acute lymphoblastic leukaemia.
    Stumpel DJ; Schneider P; van Roon EH; Pieters R; Stam RW
    Eur J Cancer; 2013 Jan; 49(1):175-84. PubMed ID: 22921182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia.
    Stumpel DJ; Schneider P; Seslija L; Osaki H; Williams O; Pieters R; Stam RW
    Leukemia; 2012 Apr; 26(4):682-92. PubMed ID: 22015773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional specificity of CpG DNA-binding CXXC domains in mixed lineage leukemia.
    Risner LE; Kuntimaddi A; Lokken AA; Achille NJ; Birch NW; Schoenfelt K; Bushweller JH; Zeleznik-Le NJ
    J Biol Chem; 2013 Oct; 288(41):29901-10. PubMed ID: 23990460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of genes transcriptionally responsive to the loss of MLL fusions in MLL-rearranged acute lymphoblastic leukemia.
    van der Linden MH; Seslija L; Schneider P; Driessen EM; Castro PG; Stumpel DJ; van Roon E; de Boer J; Williams O; Pieters R; Stam RW
    PLoS One; 2015; 10(3):e0120326. PubMed ID: 25793396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MLL-rearranged B lymphoblastic leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1.
    Juszczynski P; Rodig SJ; Ouyang J; O'Donnell E; Takeyama K; Mlynarski W; Mycko K; Szczepanski T; Gaworczyk A; Krivtsov A; Faber J; Sinha AU; Rabinovich GA; Armstrong SA; Kutok JL; Shipp MA
    Clin Cancer Res; 2010 Apr; 16(7):2122-30. PubMed ID: 20332322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MLL-rearranged infant leukaemia: A 'thorn in the side' of a remarkable success story.
    Rice S; Roy A
    Biochim Biophys Acta Gene Regul Mech; 2020 Aug; 1863(8):194564. PubMed ID: 32376390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency and clinical significance of the MLL gene rearrangements in infant acute leukemia.
    Taki T; Ida K; Bessho F; Hanada R; Kikuchi A; Yamamoto K; Sako M; Tsuchida M; Seto M; Ueda R; Hayashi Y
    Leukemia; 1996 Aug; 10(8):1303-7. PubMed ID: 8709635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A distinct set of long non-coding RNAs in childhood MLL-rearranged acute lymphoblastic leukemia: biology and epigenetic target.
    Fang K; Han BW; Chen ZH; Lin KY; Zeng CW; Li XJ; Li JH; Luo XQ; Chen YQ
    Hum Mol Genet; 2014 Jun; 23(12):3278-88. PubMed ID: 24488769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression profiling-based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infants.
    Stam RW; Schneider P; Hagelstein JA; van der Linden MH; Stumpel DJ; de Menezes RX; de Lorenzo P; Valsecchi MG; Pieters R
    Blood; 2010 Apr; 115(14):2835-44. PubMed ID: 20032505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cryptic insertion and translocation or nondividing leukemic cells disclosed by FISH analysis in infant acute leukemia with discrepant molecular and cytogenetic findings.
    Watanabe N; Kobayashi H; Ichiji O; Yoshida MA; Kikuta A; Komada Y; Sekine I; Ishida Y; Horiukoshi Y; Tsunematsu Y; Yano M; Nakadate H; Kaneko Y
    Leukemia; 2003 May; 17(5):876-82. PubMed ID: 12750700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.
    Kerstjens M; Driessen EM; Willekes M; Pinhanços SS; Schneider P; Pieters R; Stam RW
    Oncotarget; 2017 Feb; 8(9):14835-14846. PubMed ID: 27588400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia.
    Stam RW; Den Boer ML; Schneider P; de Boer J; Hagelstein J; Valsecchi MG; de Lorenzo P; Sallan SE; Brady HJ; Armstrong SA; Pieters R
    Blood; 2010 Feb; 115(5):1018-25. PubMed ID: 19965632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.